Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
895actual
Sites
132
Countries
Australia, Belgium, Brazil +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-10-31 | actual | When the study began enrolling |
| Primary completion | 2021-07-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-05 | estimated | The whole study's end, after follow-up |
| First posted | 2018-11-07 | actual | When this record first appeared on the registry |
| Results posted | 2023-06-15 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-resistant Prostate Cancer
Interventions
- Drug: olaparib — also filed as Lynparza
- Drug: abiraterone acetate — also filed as Zytiga
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment
measured Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2021-05-14 · 29.8 MB · Prot_000.pdf
Statistical Analysis Planposted 2021-05-14 · 14.7 MB · SAP_001.pdf
Publications
- PMID 42114035 — linked by the registry
- PMID 41253648 — linked by the registry
- PMID 40099663 — linked by the registry
- PMID 38452327 — linked by the registry
- PMID 38319800 — linked by the registry
- PMID 38127780 — linked by the registry
- PMID 37714168 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed